Abstract
Influenza vaccination is currently the principal means of reducing or counteracting influenza mortality and morbidity burden in the community. Since the early development of monovalent killed-virus vaccine formulations in the 1940s, different principal strategies were followed by vaccine manufactures resulting in a variety of influenza vaccines (e.g., inactivated whole-virus vaccines, live attenuated vaccines, detergent or solvent “split” vaccines, subunit vaccines, and adjuvanted vaccines). Actually two main production processes, the classical egg-based technology and more recently cell-culture-based operations, can be distinguished. In addition different routes of immunization allow the generation of intramuscular-, intradermal-, and intranasal-influenza vaccines.
The development and the production of influenza vaccines is based on a complex manufacturing process starting with the selection and development of optimal candidate vaccine viruses, and it requires various dynamic interactions with regulatory authorities and health-care officials. Planning for vaccine supplies and use as well as provision of other related health-care resources are essential components of a comprehensive seasonal and pandemic influenza response. Rapid spread of influenza viruses during seasonal epidemics and occasional pandemics tightly frames the whole process if vaccine is to be manufactured and delivered on time. There is a continuous effort to develop new and safe influenza vaccines and improve reagents for strain-specific potency testing to face complex influenza-related challenges better.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Eccles, R.: Understanding the symptoms of the common cold and influenza. Lancet Infect. Dis. 5, 718–25 (2005). doi:10.1016/S1473-3099(05)70270-X
Health topics influenza – WHO World Health Organization, Geneva, Switzerland. http://www.who.int/topics/influenza/en/ (2013)
Influenza (Seasonal) Fact sheet N°211 – WHO World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs211/en/ (2009)
Seasonal influenza (flu)/influenza (flu) viruses – CDC Centers for Disease Control and Prevention, Atlanta, USA. http://www.cdc.gov/flu/about/viruses/index.htm
Webster, R.G., Laver, W.G.: Antigenic variation in influenza virus. Biology and chemistry. Prog. Med. Virol. 13, 271–338 (1971)
Hay, A.J., Gregory, V., Douglas, A.R., Lin, Y.P.: The evolution of human influenza viruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 1861–70 (2001). doi:10.1098/rstb.2001.0999
Gasparini, R., Amicizia, D., Lai, P.L., Panatto, D.: Aflunov(®): a prepandemic influenza vaccine. Expert Rev. Vaccines 11, 145–57 (2012). doi:10.1586/erv.11.170
Beigel, J., Bray, M.: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 78, 91–102 (2008). doi:10.1016/j.antiviral.2008.01.003
Jefferson, T., et al.: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst. Rev. 18, 1 (2012). doi:10.1002/14651858.CD008965.pub3
Oxford, J., Gilbert, A., Lambkin-Williams, R.: Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/Swine (H1N1) vaccine in the current pandemic. In: Del Giudice, G., Rappuoli, R. (eds.) Influenza Vaccines for the Future, pp. 115–147. Birkhauser Inc, Basel (2011)
Verma, R., Khanna, P., Chawla, S.: Influenza vaccine: an effective preventive vaccine for developing countries. Hum. Vaccin. Immunother. 8, 675–8 (2012). doi:10.4161/hv.19516
Ellebedy, A.H., Webby, R.J.: Influenza vaccines. Vaccine 27(Suppl 4), D65–D68 (2009). doi:10.1016/j.vaccine.2009.08.038
WHO Global Influenza Surveillance Network (GISN) Surveillance and Vaccine Development – WHO Collaborating Centre for Reference and Research on Influenza (VIDRL), North Melbourne, Australia. http://www.influenzacentre.org/centre_GISN.htm
Gerdil, C.: The annual production cycle for influenza vaccine. Vaccine 21, 1776–1779 (2003). pii: S0264410X03000719
Burnet, F.M.: Growth of influenza virus in the allantoic cavity of the chick embryo. Aust. J. Exp. Biol. Med. Sci. 19, 291–295 (1941)
Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R.G.: A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U.S.A. 97, 6108–6113 (2000). doi:10.1073/pnas.100133697
Expert Committee on Biological Standardization Geneva, 17 to 21 October 2011 Proposed Generic Protocol for the Calibration of Seasonal/Pandemic Influenza Antigen Working Reagents by WHO Essential Regulatory Laboratories (WHO/BS/2011.2183). http://www.who.int/biologicals/expert_committee/BS2011.2183_Flu_vax_ERL_calibration_protocol.pdf
Hickling J., D’Hondt E. A review of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness – WHO World Health Organization Initiative for Vaccine Research Geneva Switzerland Date: 20 December 2006. www.who.int/entity/vaccine_research/diseases/influenza/Flu_vacc_manuf_tech_report.pdf
Matthews, J.T.: Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge 36, 17–24 (2006)
Rappuoli, R.: Cell-culture-based vaccine production: technological options. The Bridge 36, 25–30 (2006)
Dormitzer, P.R.: Cell culture-derived influenza vaccines. In: Del Giudice, G., Rappuoli, R. (eds.) Influenza Vaccines for the Future, pp. 293–312. Birkhauser Inc, Basel (2011)
Kistner, O., Barrett, P.N., Mundt, W., Reiter, M., Schober-Bendixen, S., Dorner, F.: Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16, 960–968 (1998). pii: S0264-410X(97)00301-0
Palache, A.M., Brands, R., van Scharrenburg, G.: Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilised chicken eggs. J. Infect. Dis. 176(Suppl 1), S20–S23 (1997)
Schild, G.C., Wood, J.M., Newman, R.W.: A single radial-immunodiffusion technique for the assay of influenza hemagglutinin antigen. WHO Bull. 52, 223–231 (1975)
Wood, J.M., Schild, G.C., Newman, R.W., Seagroatt, V.: Application of an improved single radial-immunodiffusion technique for the assay of influenza hemagglutinin antigen content of whole virus and subunit vaccines. Dev. Biol. Stand. 39, 193–200 (1977)
Recommendations for the production and control of influenza vaccine (inactivated) © World Health Organization WHO Technical Report Series, No. 927, Annex 3 (2005), http://www.who.int/vaccine_research/diseases/influenza/TRS_927_ANNEX_3_Influenza_2005.pdf
Wood, J.M., Levandowski, R.A.: The influenza vaccine licensing process. Vaccine 21, 1786–1788 (2003). pii: S0264410X03000732
Sambhara, S., Rappuoli, R.: Improving influenza vaccines. Expert Rev. Vaccines 11, 871–872 (2012). doi:10.1586/erv.12.79
Dormitzer, P.R., Tsai, T.F., Del Giudice, G.: New technologies for influenza vaccines. Hum. Vaccin. Immunother. 8, 45–58 (2012). doi:10.4161/hv.8.1.18859
Montomoli, E., et al.: Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev. Vaccines 11, 587–94 (2012). doi:10.1586/erv.12.24
Strecker, T., et al.: Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens. Clin. Chem. Lab. Med. 50, 1275–9 (2012). doi:10.1515/cclm-2011-0650
WHO Writing Group, Ampofo W. K. et al.: Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010. Influenza Other Respi. Viruses. 6, 142–152 (2012). doi: 10.1111/j.1750-2659.2011.00277.x
Kapteyn, J.C., et al.: HPLC-based quantification of haemagglutinin in the production of egg and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 27, 1468–77 (2009). doi:10.1016/j.vaccine.2008.11.113
Lorbetskie, B., et al.: Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 29, 3377–89 (2011). doi:10.1016/j.vaccine.2011.02.090
Williams, T.L., et al.: Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 26, 2510–20 (2008). doi:10.1016/j.vaccine.2008.03.014
Cox, M.M.: Recombinant protein vaccines produced in insect cells. Vaccine 30, 1759–66 (2012). doi:10.1016/j.vaccine.2012.01.016
Baxter, R., et al.: Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 29, 2272–8 (2011). doi:10.1016/j.vaccine.2011.01.039
Song, L., et al.: Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 3, e2257 (2008). doi:10.1371/journal.pone.0002257
Kang, S.M., Kim, M.C., Compans, R.W.: Virus-like particles as universal influenza vaccines. Expert Rev. Vaccines 11, 995–1007 (2012). doi:10.1586/erv.12.70
Haynes, J.R.: Influenza virus-like particle vaccines. Expert Rev. Vaccines 8, 435–45 (2009). doi:10.1586/erv.09.8
Gasparini, R., Amicizia, D., Lai, P.L., Panatto, D.: Live attenuated influenza vaccine–a review. J. Prev. Med. Hyg. 52, 95–101 (2011)
Monto, A.S., et al.: Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 361, 1260–7 (2009). doi:10.1056/NEJMoa0808652
Carter, N.J., Curran, M.P.: Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71, 1591–622 (2011). doi:10.2165/11206860-000000000-00000
Kopecky-Bromberg, S.A., Palese, P.: Recombinant vectors as influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 243–67 (2009). doi:10.1007/978-3-540-92165-3_13
Lambe, T.: Novel viral vectored vaccines for the prevention of influenza. Mol. Med. 18, 1153–60 (2012). doi:10.2119/molmed.2012.00147
O’Hagan, D.T., Tsai, T., Reed, S.: Emulsion-based adjuvants for improved influenza vaccines. In: Del Giudice, G., Rappuoli, R. (eds.) Influenza Vaccines for the Future, pp. 327–357. Birkhauser Inc, Basel (2011)
Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., et al.: Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28, 563–571 (2009). doi:10.1097/INF.0b013e31819d6394
Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., et al.: Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365, 1406–16 (2011). doi:10.1056/NEJMoa1010331
Heikkinen, T., Young, J., van Beek, E., Franke, H., Verstraeten, T., et al.: Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am. J. Obstet. Gynecol. 207, 177.e1–8 (2012). doi:10.1016/j.ajog.2012.07.007
Ambrose, C.S., Levin, M.J.: The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 8, 81–88 (2012). doi:10.4161/hv.8.1.17623
Barr, I.G., Jelley, L.L.: The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 72, 2177–85 (2012). doi:10.2165/11641110-000000000-00000
Shaw, A.R.: Universal influenza vaccine: the holy grail? Expert Rev. Vaccines 11, 923–927 (2012). doi:10.1586/erv.12.73
Du, L., Zhou, Y., Jiang, S.: Research and development of universal influenza vaccines. Microbes Infect. 12, 280–6 (2010). doi:10.1016/j.micinf.2010.01.001
Kang, S.M., Song, J.M., Compans, R.W.: Novel vaccines against influenza viruses. Virus Res. 162, 31–38 (2011). doi:10.1016/j.virusres.2011.09.037
Rudolph, W., Ben Yedidia, T.: A universal influenza vaccine: where are we in the pursuit of this “Holy Grail”? Hum. Vaccin. 7, 10–11 (2011). pii: 14925
Belshe, R.B., Newman, F.K., Cannon, J., Duane, C., Treanor, J., et al.: Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351, 2286–94 (2004). doi:10.1056/NEJMoa043555
Kenney, R.T., Frech, S.A., Muenz, L.R., Villar, C.P., Glenn, G.M.: Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351, 2295–301 (2004). doi:10.1056/NEJMoa043540
Ansaldi, F., Durando, P., Icardi, G.: Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin. Biol. Ther. 11, 415–27 (2011). doi:10.1517/14712598.2011.557658
Acknowledgements
The authors are grateful to Heidi Trusheim and Karsten Kattmann for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hilleringmann, M., Jobst, B., Baudner, B.C. (2014). Influenza Cell-Culture Vaccine Production. In: Giese, M. (eds) Molecular Vaccines. Springer, Cham. https://doi.org/10.1007/978-3-319-00978-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-319-00978-0_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-00977-3
Online ISBN: 978-3-319-00978-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)